Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02422498 · ClinicalTrials.gov registry record · Phase 2
Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
A Phase 2 study of Locally Recurrent/Metastatic Triple Negative Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
- 7
- Study locations
NCT02422498 is a Phase 2 study of Locally Recurrent/Metastatic Triple Negative Breast Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 49 participants. The trial reports 7 study locations across 2 states.
The verdict
NCT02422498, a Phase 2 study of Locally Recurrent/Metastatic Triple Negative Breast Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
- 7
- Study locations
Study Summary
The study is being done to find out if the results of a pre-treatment biopsy can predict response to cisplatin and radiation treatment for patients with metastatic or recurrent triple negative breast cancer.
Conditions Studied
Interventions
- DRUG cisplatin
- RADIATION external beam radiation therapy
- PROCEDURE Biopsy of Target Tumor
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering at Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2015-04-14 |
| Est. Completion | 2022-12-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02422498
The ClinicalTrials.gov registry entry for NCT02422498 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Recurrent/Metastatic Triple Negative Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which cisplatin is the first listed.
NCT02422498 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02422498 about?
NCT02422498 is a clinical study titled "Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy". The study is being done to find out if the results of a pre-treatment biopsy can predict response to cisplatin and radiation treatment for patients with metastatic or recurrent triple negative breast cancer.
What is the current status of trial NCT02422498?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2015-04-14. Estimated completion is 2022-12-19.
What conditions does trial NCT02422498 study?
This clinical trial studies the following conditions: Locally Recurrent/Metastatic Triple Negative Breast Cancer.
What interventions are being tested in trial NCT02422498?
The interventions under investigation include: cisplatin (DRUG), external beam radiation therapy (RADIATION), Biopsy of Target Tumor (PROCEDURE).
Who is sponsoring clinical trial NCT02422498?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02422498 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.